Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma

British Journal of Haematology

Volumn 171, Issue 4, 2015, Pages 463-470

  Oki, Yasuhiro ^a   Fanale, Michelle ^a   Romaguera, Jorge ^a   Fayad, Luis ^a   Fowler, Nathan ^a   Copeland, Amanda ^a   Samaniego, Felipe ^a   Kwak, Larry W ^a   Neelapu, Sattva ^a   Wang, Michael ^a   Feng, Lei ^a   Younes, Anas ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

AKT; Clinical trials; Lymphoma; Target therapy

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; ALPHA2 INTERFERON; ASPARTATE AMINOTRANSFERASE; CREATININE; EOTAXIN; EPIDERMAL GROWTH FACTOR; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLUCOSE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; LYMPHOTOXIN; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASCULOTROPIN; AKT1 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; CYTOKINE; FUSED HETEROCYCLIC RINGS; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR; TUMOR PROTEIN;

ADULT; AGED; ANEMIA; ANGIOIMMUNOBLASTIC T CELL LYMPHOMA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER RECURRENCE; CLASSICAL HODGKIN LYMPHOMA; CONJUNCTIVITIS; CONSTIPATION; DIARRHEA; DRUG ACTIVITY; DRUG DOSE INCREASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; FATIGUE; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; LARGE CELL LYMPHOMA; LYMPHOCYTOMA; LYMPHOCYTOPENIA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PERIPHERAL T CELL LYMPHOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PRURITUS; RASH; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; VERY ELDERLY; ANTAGONISTS AND INHIBITORS; AUTOTRANSPLANTATION; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG EFFECTS; DRUG ERUPTIONS; ENZYMOLOGY; FEEDBACK SYSTEM; GASTROINTESTINAL DISEASE; HEMATOLOGIC DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; KAPLAN MEIER METHOD; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; RECURRENT DISEASE; SALVAGE THERAPY; TREATMENT OUTCOME; TUMOR VOLUME; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; CYTOKINES; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ERUPTIONS; FEEDBACK, PHYSIOLOGICAL; FEMALE; GASTROINTESTINAL DISEASES; HEMATOLOGIC DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HETEROCYCLIC COMPOUNDS, 3-RING; HODGKIN DISEASE; HUMANS; HYPERGLYCEMIA; KAPLAN-MEIER ESTIMATE; LYMPHOMA; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; RECURRENCE; SALVAGE THERAPY; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; TUMOR BURDEN; YOUNG ADULT;

EID: 84945486833     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13603     Document Type: Article

References (33)

1. Bertacchini, J., Guida, M., Accordi, B., Mediani, L., Martelli, A.M., Barozzi, P., Petricoin, 3rd, E., Liotta, L., Milani, G., Giordan, M., Luppi, M., Forghieri, F., De Pol, A., Cocco, L., Basso, G. & Marmiroli, S. (2014) Feedbacks and adaptive capabilities of the PI3K/Akt/mTOR axis in acute myeloid leukemia revealed by pathway selective inhibition and phosphoproteome analysis. Leukemia, 28, 2197-2205.
2. Biondo, A., Yap, T.A., Yan, L., Patnaik, A., Fearen, I., Baird, R.D., Papadopoulos, K.P., Delgado, L.M., Taylor, A., Lupinacci, L., Blackman, S.C., Decordova, S., Tall, M., Heaton, S., Garrett, M.D., Sullivan, D., Bono, J.S.D. & Tolcher, A.W. (2011) Phase I clinical trial of an allosteric AKT inhibitor, MK-2206, using a once weekly (QW) dose regimen in patients with advanced solid tumors. Journal of Clinical Oncology, 29, abstr 3037.
3. Cheson, B.D., Pfistner, B., Juweid, M.E., Gascoyne, R.D., Specht, L., Horning, S.J., Coiffier, B., Fisher, R.I., Hagenbeek, A., Zucca, E., Rosen, S.T., Stroobants, S., Lister, T.A., Hoppe, R.T., Dreyling, M., Tobinai, K., Vose, J.M., Connors, J.M., Federico, M. & Diehl, V. (2007) Revised response criteria for malignant lymphoma. Journal of Clinical Oncology, 25, 579-586.
4. Dreyling, M., Morschhauser, F., Bron, D., Bouabdallah, K., Vitolo, U., Linton, K., Van Den Neste, E., Mappa, S., Giurescu, M., Childs, B.H. & Zinzani, P.L. (2013) Preliminary results of a phase II study of single agent Bay 80-6946, a novel PI3K inhibitor, in patients with relapsed/refractory, indolent or aggressive lymphoma. Blood, 122, abstr 87.
5. Engelman, J.A. (2009) Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nature Reviews Cancer, 9, 550-562.
6. Flinn, I.W., Brown, J.R., Byrd, J.C., Coutre, S.E., Wagner-Johnston, N.D., Kahl, B.S., Spurgeon, S.E., Benson, D.M., Peterman, S., Johnson, D., Li, D., Dansey, R.D., Jahn, T.M. & Furman, R.R. (2013a) Final report of a phase I study of idelalisib (GS-1101) a selective inhibitor of PI3Kd, in patients with relapsed or refractory CLL. Hematological Oncology, 31, abstr 297.
7. Flinn, I., Patel, M., Kahl, B.S., Horwitz, S.M., Foss, F.M., Oki, Y., Porcu, P., Sweeney, J., Allen, K., Faia, K., Harris, P., Dunbar, J., Stern, H.M., Kelly, P. & O'Brien, S. (2013b) Preliminary safety and efficacy of IPI-145, a potent inhibitor of phosphoinositide-3-kinase-δ, γ, in patients with chronic lymphocytic leukemia. Blood, 122, abstr 677.
8. Georgakis, G.V. & Younes, A. (2006) From Rapa Nui to rapamycin: targeting PI3K/Akt/mTOR for cancer therapy. Expert Review of Anticancer Therapy, 6, 131-140.
9. Gopal, A.K., Kahl, B.S., de Vos, S., Wagner-Johnston, N.D., Schuster, S.J., Jurczak, W.J., Flinn, I.W., Flowers, C.R., Martin, P., Viardot, A., Blum, K.A., Goy, A.H., Davies, A.J., Zinzani, P.L., Dreyling, M., Johnson, D., Miller, L.L., Holes, L., Li, D., Dansey, R.D., Godfrey, W.R. & Salles, G.A. (2014) PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. New England Journal of Medicine, 370, 1008-1018.
10. Hay, N. (2005) The Akt-mTOR tango and its relevance to cancer. Cancer Cell, 8, 179-183.
11. Hirai, H., Sootome, H., Nakatsuru, Y., Miyama, K., Taguchi, S., Tsujioka, K., Ueno, Y., Hatch, H., Majumder, P.K., Pan, B.S. & Kotani, H. (2010) MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Molecular Cancer Therapeutics, 9, 1956-1967.
12. Horwitz, S.M., Porcu, P., Flinn, I., Kahl, B.S., Sweeney, J., Stern, H.M., Douglas, M., Allen, K., Kelly, P. & Foss, F.M. (2014) Duvelisib (IPI-145), a phosphoinositide-3-kinase-d, ? inhibitor, shows activity in patients with relapsed/refractory T-cell lymphoma. Blood, 124, abstr 803.
13. Jia, S., Liu, Z., Zhang, S., Liu, P., Zhang, L., Lee, S.H., Zhang, J., Signoretti, S., Loda, M., Roberts, T.M. & Zhao, J.J. (2008) Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature, 454, 776-779.
14. Johnston, P.B., Pinter-Brown, L.C., Rogerio, J.W., Warsi, G., Chau, Q. & Ramchandren, R. (2012a) Everolimus (EVE) for relapsed/refractory classical Hodgkin lymphoma (cHL): open-label, single-arm, phase II study. Journal of Clinical Oncology, 30, abstr 8028.
15. Johnston, P.B., Pinter-Brown, L., Rogerio, J., Warsi, G., Chau, Q. & Ramchandren, R. (2012b) Everolimus for relapsed/refractory classical hodgkin lymphoma: multicenter, open-label, single-arm, phase 2 study. Blood, 120, abstr 2740.
16. Kahl, B.S., Spurgeon, S.E., Furman, R.R., Flinn, I.W., Coutre, S.E., Brown, J.R., Benson, D.M., Byrd, J.C., Peterman, S., Cho, Y., Yu, A., Godfrey, W.R. & Wagner-Johnston, N.D. (2014) A phase 1 study of the PI3Kdelta inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). Blood, 123, 3398-3405.
17. Konopleva, M.Y., Walter, R.B., Faderl, S.H., Jabbour, E.J., Zeng, Z., Borthakur, G., Huang, X., Kadia, T.M., Ruvolo, P.P., Feliu, J.B., Lu, H., Debose, L., Burger, J.A., Andreeff, M., Liu, W., Baggerly, K.A., Kornblau, S.M., Doyle, L.A., Estey, E.H. & Kantarjian, H.M. (2014) Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia. Clinical Cancer Research, 20, 2226-2235.
18. Li, Z., Yan, S., Attayan, N., Ramalingam, S. & Thiele, C.J. (2012) Combination of an allosteric Akt Inhibitor MK-2206 with etoposide or rapamycin enhances the antitumor growth effect in neuroblastoma. Clinical Cancer Research, 18, 3603-3615.
19. Molife, L.R., Yan, L., Vitfell-Rasmussen, J., Zernhelt, A.M., Sullivan, D.M., Cassier, P.A., Chen, E., Biondo, A., Tetteh, E., Siu, L.L., Patnaik, A., Papadopoulos, K.P., de Bono, J.S., Tolcher, A.W. & Minton, S. (2014) Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors. Journal of Hematology & Oncology, 7, 1.
20. Osaki, M., Oshimura, M. & Ito, H. (2004) PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis, 9, 667-676.
21. Petrich, A.M., Leshchenko, V., Kuo, P.Y., Xia, B., Thirukonda, V.K., Ulahannan, N., Gordon, S., Fazzari, M.J., Ye, B.H., Sparano, J.A. & Parekh, S. (2012) Akt inhibitors MK-2206 and nelfinavir overcome mTOR inhibitor resistance in diffuse large B-cell lymphoma. Clinical Cancer Research, 18, 2534-2544.
22. Renner, C., Zinzani, P., Gressin, R., Klingbiel, D., Dietrich, P.Y., Hitz, F., Bargetzi, M., Mingrone, W., Martinelli, G., Trojan, A., Bouabdallah, K., Lohri, A., Gyan, E., Biaggi, C., Cogliatti, S., Bertoni, F., Ghielmini, M., Brauchli, P. & Ketterer, N. (2012) A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma. Haematologica, 97, 1085-1091.
23. Rodon, J., Dienstmann, R., Serra, V. & Tabernero, J. (2013) Development of PI3K inhibitors: lessons learned from early clinical trials. Nature Reviews. Clinical Oncology, 10, 143-153.
24. Smith, S.M., van Besien, K., Karrison, T., Dancey, J., McLaughlin, P., Younes, A., Smith, S., Stiff, P., Lester, E., Modi, S., Doyle, L.A., Vokes, E.E. & Pro, B. (2010) Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: the University of Chicago phase II consortium. Journal of Clinical Oncology, 28, 4740-4746.
25. Vivanco, I. & Sawyers, C.L. (2002) The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nature Reviews Cancer, 2, 489-501.
26. Witzig, T.E., Geyer, S.M., Ghobrial, I., Inwards, D.J., Fonseca, R., Kurtin, P., Ansell, S.M., Luyun, R., Flynn, P.J., Morton, R.F., Dakhil, S.R., Gross, H. & Kaufmann, S.H. (2005) Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. Journal of Clinical Oncology, 23, 5347-5356.
27. Witzig, T.E., Reeder, C.B., LaPlant, B.R., Gupta, M., Johnston, P.B., Micallef, I.N., Porrata, L.F., Ansell, S.M., Colgan, J.P., Jacobsen, E.D., Ghobrial, I.M. & Habermann, T.M. (2011) A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia, 25, 341-347.
28. Yap, T.A., Yan, L., Patnaik, A., Fearen, I., Olmos, D., Papadopoulos, K., Baird, R.D., Delgado, L., Taylor, A., Lupinacci, L., Riisnaes, R., Pope, L.L., Heaton, S.P., Thomas, G., Garrett, M.D., Sullivan, D.M., de Bono, J.S. & Tolcher, A.W. (2011) First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. Journal of Clinical Oncology, 29, 4688-4695.
29. Yee, K.W., Zeng, Z., Konopleva, M., Verstovsek, S., Ravandi, F., Ferrajoli, A., Thomas, D., Wierda, W., Apostolidou, E., Albitar, M., O'Brien, S., Andreeff, M. & Giles, F.J. (2006) Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clinical Cancer Research, 12, 5165-5173.
30. Younes, A., Moskowitz, A.J., Moskowitz, C.H., Fanale, M.A., Shustov, A., Peterman, S., Johnson, D., Zhou, L., Dansey, R.D., Godfrey, W.R. & Gopal, A.K. (2013) Pilot phase 2 study of idelalisib, a selective inhibitor of PI3Kd, in patients with heavily pretreated hodgkin lymphoma (HL). Hematological Oncology, 31, abstr 139.
31. Younes, A., Salles, G., Bociek, R.G., Martinelli, G., Caballero, D., Barca, E.G., Mukherjee, N., Williams, L., Herbst, F., Tavorath, R. & Kim, W.S. (2014) An open-label phase II study of buparlisib (BKM120) in patients with relapsed and refractory diffuse large B-cell lymphoma, mantle cell lymphoma or follicular lymphoma. Blood, 124, abstr 1718.
32. Yuan, T.L. & Cantley, L.C. (2008) PI3K pathway alterations in cancer: variations on a theme. Oncogene, 27, 5497-5510.
33. Zent, C.S., LaPlant, B.R., Johnston, P.B., Call, T.G., Habermann, T.M., Micallef, I.N. & Witzig, T.E. (2010) The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation. Cancer, 116, 2201-2207.